NICE no for CML drugs follows Glivec price increase
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has said a preliminary "no" to Bristol-Myers Squibb's Sprycel (dasatinib), Novartis' Tasigna (nilotinib) and high-dose Glivec (imatinib) for treating chronic myeloid leukaemia (CML) that is resistant to standard-dose imatinib, because of what it said was weak evidence supporting the drugs' effectiveness and doubts about the economic models put forward. The "no" also follows an increase in the cost of Glivec.